XM non fornisce servizi ai residenti degli Stati Uniti d'America.

XM non fornisce servizi ai residenti degli Stati Uniti d'America.
P
P

Pfizer

News

Reuters - 5 giorni fa

U.S. STOCKS Pure Cycle, Tesla, Five9

BUZZ-U.S. STOCKS ON THE MOVE-Pure Cycle, Tesla, Five9 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 fell from record highs on Thursday, weighed by megacap stocks, as investors favored small-caps after a softer-than-expected inflation reading bolstered hopes that the U.S.
A
A
B
C
C
C
F
I
P
P
P
T
V
D
W
U
U
E
Reuters - 5 giorni fa

U.S. STOCKS Delta Air Lines, Crypto stocks, Solar stocks

BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Crypto stocks, Solar stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes struggled for direction on Thursday as investors favored rate-sensitive small-cap stocks over expensive megacaps after a softer-than-expected inflation reading bolstered hopes for monetary policy easing in September.
A
B
C
C
F
N
P
P
P
V
L
A
W
U
U
I
M
R
Reuters - 5 giorni fa

U.S. STOCKS Alcoa, 40, Broadcom

BUZZ-U.S. STOCKS ON THE MOVE-Alcoa, WD-40, Broadcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street futures turned positive on Thursday after data showed inflation eased in June, boosting expectations of
A
B
C
C
P
P
P
V
L
W
U
R
Reuters - 5 giorni fa

Wall Street set for stronger open after inflation print; airlines slump on Delta forecast

US STOCKS-Wall Street set for stronger open after inflation print; airlines slump on Delta forecast CPI data shows inflation eased in June PepsiCo dips on quarterly revenue miss Pfizer moves ahead with once-daily weight-loss pill, shares up Futures up: Dow 0.17%, S&P 500 0.22%, Nasdaq 0.28% Updated at 8:42 a.m. ET/1242 GMT By Lisa Pauline Mattackal and Ankika Biswas July 11 (Reuters) - Wall Street futures turned positive on Thursday after data showed inflation eased in June, boosting expectation
A
J
N
P
P
A
U
U
U
U
A
Reuters - 5 giorni fa

Pfizer's move to press ahead with weight-loss pill drags some drug developers

BUZZ-Pfizer's move to press ahead with weight-loss pill drags some drug developers Updates ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.3% to $55.50 premarket ** Pfizer PFE.N plans to advance a reworked, once-a-day version of its experimental obesity pill, danuglipron, to clinical trials in the second half of this year
P
Reuters - 5 giorni fa

U.S. STOCKS Costco, PepsiCo, Alcoa

BUZZ-U.S. STOCKS ON THE MOVE-Costco, PepsiCo, Alcoa Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. index futures slipped on Thursday on expectations that a key inflation print could shaperate-cuts bets and put Wall Street's record-breaking run to the test, while Delta Air Lines slumpedafter a weak forecast, dragging other airline stocks.
A
C
C
P
P
P
V
L
W
U
Reuters - 5 giorni fa

Pfizer's move to press ahead with weight-loss pill drags some developers

BUZZ-Pfizer's move to press ahead with weight-loss pill drags some developers Updates ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.8% to $55.22 premarket ** Pfizer PFE.N plans to advance a reworked, once-a-day version of its experimental obesity pill, danuglipron, to clinical trials in the second half of this year ** I
P
Reuters - 5 giorni fa

Futures edge lower ahead of inflation test; Delta Airlines falls

US STOCKS-Futures edge lower ahead of inflation test; Delta Airlines falls For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. CPI, weekly jobless claims data due at 8:30 a.m. ET PepsiCo dips on quarterly revenue miss Citigroup falls after US regulators slap $136-million fine Pfizer moves ahead with once-daily weight-loss pill, shares up Futures down: Dow 0.13%, S&P 500 0.11%, Nasdaq 0.08% Updated at 7:03 a.m.
A
C
J
N
P
P
A
U
U
U
U
A
Reuters - 5 giorni fa

Pfizer Advances Development Of Once-Daily Formulation Of Oral 1 Receptor Agonist Danuglipron

BRIEF-Pfizer Advances Development Of Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron July 11 (Reuters) - Pfizer Inc PFE.N : PFIZER ADVANCES DEVELOPMENT OF ONCE-DAILY FORMULATION OF ORAL GLP-1 RECEPTOR AGONIST DANUGLIPRON PFIZER INC - ONGOING STUDY SHOWS FAVORABLE PHARMACOKINETIC PROFILE FOR DANUGLIPRON PFIZER INC - TO CONDUCT DOSE
P
Reuters - 5 giorni fa

Viking hit by Pfizer's plan for once-daily weight loss pill

BUZZ-Viking hit by Pfizer's plan for once-daily weight loss pill ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.8% to $55.22 premarket ** Pfizer PFE.N says it will advance a reworked, once-a-day version of its experimental obesity pill, danuglipron to clinical trials in the second half of this year ** In March, VKTX said
P
Reuters - 5 giorni fa

Pfizer rises after moving forward with once-daily weight loss drug

BUZZ-Pfizer rises after moving forward with once-daily weight loss drug ** Shares of drugmaker Pfizer PFE.N rise 3.7% to $29.40 premarket ** Co says it will conduct studies in H2 2024 on a reworked, once-daily version of its experimental obesity pill, danuglipron ** PFE is testing the once-daily modified release dosing as well as a twice-daily form
P
Reuters - 5 giorni fa

Pfizer moves forward with once-daily weight-loss pill

UPDATE 4-Pfizer moves forward with once-daily weight-loss pill Adds details on timeframe in paragraph 4, analyst comment in paragraphs 7-8 By Michael Erman and Manas Mishra July 11 (Reuters) - Pfizer PFE.N plans to move a reworked, once -a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year.
A
P
Reuters - 5 giorni fa

Pfizer moves forward with once-daily weight loss drug

Pfizer moves forward with once-daily weight loss drug July 11 (Reuters) - Pfizer PFE.N said on Thursday it would conduct studies in the second-half of 2024 on a reworked, once-a-day version of its experimental obesity pill, danuglipron. The drugmaker last year said it was focusing on danuglipron's development after scrapping a separate, once-daily pill due to concerns about liver safety.
P
Reuters - 6 giorni fa

BNP Paribas, Mistral AI ink partnership deal

RPT-BRIEF-Evotec And Pfizer Collaborate To Advance Drug Discovery In France Repeats brief to connect to snaps, no changes to text July 10 (Reuters) - EVOTEC SE EVTG.DE : EVOTEC AND PFIZER COLLABORATE TO ADVANCE DRUG DISCOVERY IN FRANCE MULTI-YEAR COLLABORATION WILL INITIALLY FOCUS ON EARLY DISCOVERY RESEARCH FOR METABOLIC AND INFECTIOUS DISEASES AN
P
Reuters - 1 settimana fa

Column: SEC blasts Pfizer's bid for $75 million from insider trading victims' fund

Column: SEC blasts Pfizer's bid for $75 million from insider trading victims' fund The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel July 9 (Reuters) - One of the most notorious insider trading schemes in U.S. history has led to a $75 million fight between drugmaker Pfizer and the U.S. Securities and Exchange Commission.
P
Reuters - 1 settimana fa

FLiRT COVID variants: What are they and are they more contagious?

EXPLAINER-FLiRT COVID variants: What are they and are they more contagious? Adds details on KP.3 variant, U.S. vaccines By Michael Erman NEW YORK, July 9 (Reuters) - The so-called FLiRT variants of SARS-CoV-2 coronavirus that cause COVID-19 have been the dominant forms of the virus circulating this year globally, according to the World Health Organization FLiRT is an acronym for the locations of the mutations the variants share on the virus' spike protein.
P
Reuters - 1 settimana fa

Pfizer's chief scientist Mikael Dolsten to step down

UPDATE 2-Pfizer's chief scientist Mikael Dolsten to step down Adds background throughout, CEO quote in paragraph 5 July 9 (Reuters) - Pfizer PFE.N said on Tuesday Chief Scientific Officer Mikael Dolsten, a key figure behind the development of its COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker. Dolsten, aged 65, served as the head of Pfizer's research and development after he joined the company through its $68 billion acquisition of Wyeth in 2009. He became th
P
Reuters - 1 settimana fa

Pfizer Chief Scientific Officer Mikael Dolsten to step down

Pfizer Chief Scientific Officer Mikael Dolsten to step down July 9 (Reuters) - Pfizer PFE.N said on Tuesday its chief scientific officer Mikael Dolsten would step down after more than 15 years with the drugmaker. Reporting by Christy Santhosh; Editing by Shilpi Majumdar
P
Reuters - 1 settimana fa

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births By Christy Santhosh July 8 (Reuters) - Pfizer's PFE.N respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots. The vaccine Abrysvo was approved by the U.S.
G
P
Reuters - 1 settimana fa

Lilly beefs up bowel disease drug portfolio with $3.2 bln Morphic deal

UPDATE 4-Lilly beefs up bowel disease drug portfolio with $3.2 bln Morphic deal Updates share movement in paragraph 2 By Sriparna Roy July 8 (Reuters) - Eli Lilly LLY.N agreed to buy Morphic Holding MORF.O for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its footprint in the multi-billion dollar market.
P

Condizioni

Asset popolari

Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.

Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.

Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.

Avvertenza sul rischio: Il tuo capitale è a rischio. I prodotti con leva finanziaria possono non essere adatti a tutti. Ti chiediamo di consultare attentamente la nostra Informativa sul rischio.